
May 6, 2026
Tempus tool will identify patients for Alzheimer’s blood testing
Lucent Diagnostics has partnered with Tempus AI to enhance Alzheimer’s disease detection through blood-based biomarker testing.The collaboration aims to integrate LucentAD® Complete, a multi-biomarker blood test, into Tempus' clinical ordering platform. This initiative seeks to streamline the identification of patients eligible for Alzheimer’s biomarker testing, addressing a significant gap in current clinical practices. With over 7 million Americans affected by Alzheimer’s, many remain undiagno









